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Comprehensive sequencing of the 
myocilin gene in a selected cohort 
of severe primary open-angle 
glaucoma patients
Luke o’Gorman  1, Angela J. Cree  2, Daniel Ward  3, Helen L. Griffiths2, Roshan sood4, 
Alastair K. Denniston  5, Jay e. self2,6, sarah ennis7, Andrew J. Lotery  2,6 & Jane Gibson  4
primary open-angle glaucoma (poAG) is the most common form of glaucoma, prevalent in 
approximately 1–2% of Caucasians in the UK over the age of 40. It is characterised by an open anterior 
chamber angle, raised intraocular pressure (IOP) and optic nerve damage leading to loss of sight. The 
myocilin gene (MYOC) is the most common glaucoma-causing gene, accounting for ~2% of British POAG 
cases. 358 patients were selected for next generation sequencing (NGS) with the following selection 
criteria: Caucasian ethnicity, intraocular pressure (IOP) 21–40 mm Hg, cup:disc ratio ≥0.6 and visual 
field mean deviation ≤−3. The entire MYOC gene (17,321 bp) was captured including the promoter, 
introns, UTRs and coding exons. We identify 12 exonic variants (one stop-gain, five missense and 
six synonymous variants), two promoter variants, 133 intronic variants, two 3′ UTR variants and 23 
intergenic variants. Four known or predicted pathogenic exonic variants (p.R126W, p.K216K, p.Q368* 
and p.T419A) were identified across 11 patients, which accounts for 3.07% of this POAG cohort. This is 
the first time that the entire region of MYOC has been sequenced and variants reported for a cohort of 
poAG patients.
primary open-angle glaucoma
Glaucoma accounts for 7.9% of blindness in the UK1. It is characterised by a progressive loss of retinal ganglion 
cells, atrophy of the optic nerve and degradation of the visual field2. Glaucoma presents in multiple forms with 
primary open-angle (POAG) being the most common form3,4.
POAG is characterised by an open anterior chamber angle and raised intraocular pressure (IOP) leading to 
damage of the optic nerve and visual field loss3. POAG affects at least 1% of Caucasians in the UK over the age 
of 40 years5. Normal tension glaucoma (NTG) is a form of POAG in which optic nerve damage and visual field 
degradation are characteristic traits, however, IOP is not elevated4.
Approximately 5% of POAG is accounted for by monogenic, Mendelian-like variants. The myocilin gene 
(MYOC) accounts for the majority, approximately 2.2% of cases6. The optineurin gene (OPTN) may contribute to 
POAG in some populations, but has been implicated in normal tension glaucoma where is accounts for 1.5% of 
cases7. The majority of POAG cases are assumed to be accounted for by combined effects of multiple genetic and 
non-genetic risk factors. IOP is considered the most important risk factor in POAG. Other important risk factors 
in POAG include age, race, refractive error, central corneal thickness and family history of POAG5,8,9. However, 
these risk factors alone do not cause glaucoma7.
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Myocilin
MYOC is understood to have a role in cytoskeletal development and regulation of intraocular pressure (IOP)10. 
It is also known as the trabecular meshwork glucocorticoid-inducible response protein (TIGR)10,11. Variants 
in MYOC have also previously been identified as the cause of hereditary juvenile-onset open-angle glaucoma 
(JOAG), which is an early onset (<40 years) sub-set of POAG12–15.
MYOC is expressed in multiple tissues within the eye including the trabecular meshwork and ciliary body 
suggesting that it causes an increase in IOP through obstruction of the aqueous outflow14,16. It is also expressed 
at similar levels in a range of organs and tissue including the heart, skeletal muscle and bone marrow amongst 
others17.
The MYOC gene is encoded on the negative strand and comprises three exons. MYOC has one known RefSeq 
transcript (NM_000261.1) and spans 17,321 bp18,19. MYOC encodes a 504 amino acid polypeptide which consists 
of an N-terminal helix-turn-helix domain and two coil-coils20 and can homodimerise through leucine zipper 
interactions21. The C-terminal olfactomedin-like domain22 is part of a family of mucus proteins which are mainly 
found in nasal mucus23.
Known variants in MYOC are curated and made available online via the ‘myocilin allele-specific glaucoma 
phenotype database’24. Within this database, exons 1, 2 and 3 have 32, 1 and 62 known glaucoma-causing variants 
respectively. There are no glaucoma-causing variants annotated in the promoter, intronic or intergenic regions 
currently (27/11/2017)24. The database reports disease-causing variants comprising missense (83.7%), non-
sense (5.8%), <21 bp deletion (4.8%), <21 bp insertion (4.8%) and <21 bp indels (1%). The Exome Aggregation 
Consortium (ExAC)25 scores the probability of loss-of-function intolerance (pLI) as 0.00 indicating that MYOC 
is tolerant of loss-of-function, and MYOC homozygous knockout mice experiments have excluded haploinsuffi-
ciency as a disease mechanism underlying POAG26. Shepard et al. suggested a gain-of-function is the likely cause 
of POAG and concluded p.Y437H variants in human MYOC induce exposure of an N-terminal cryptic peroxi-
somal targeting signal sequence16. The majority of pathogenic MYOC variants are found in exon 36,27 where the 
most prevalent pathogenic variants are found to have a penetrance of up to 90%17. The concentration of known 
variants in exon 3 may have been exacerbated in recent years due to preferential analysis of this exon. Since the 
MYOC gene involves an autosomal dominant mode of inheritance in POAG14, pathogenic heterozygous variants 
would be a sufficient genotype for causality.
Aim
In this study, the entire region of MYOC is assessed in 358 individuals with POAG selected from a UK cohort. 
Through the use of next-generation sequencing (NGS), application of bioinformatic tools and strategic filtering 
of variants, variants across the intergenic, promoter, UTR, exonic coding sequences and intronic regions are 
reported for the first time.
Methods
Patients with Primary Open Angle Glaucoma (POAG) were recruited from eye clinics at University Hospital 
Southampton, Addenbrook’s Hospital Cambridge, Frimley Park Hospital Surrey, Queen Elizabeth Hospital 
Birmingham, Queen Alexandra Hospital Portsmouth, Romsey Hospital, St Mary’s Hospital Isle of Wight, Torbay 
Hospital Devon and New Cross Hospital Wolverhampton. Patient data was collected including gender, ethnicity, 
family history of POAG, specific diagnosis of the patient, age at diagnosis, intraocular pressure (IOP), cup:-
disc ratio (CDR), central corneal thickness and visual field mean deviation (VFMD). Blood samples were col-
lected and DNA was extracted using the salting out method28 and stored at −20 °C. Initially, 372 patients were 
selected for Next Generation Sequencing (NGS) using the following selection criteria: Caucasian ethnicity, 21 mm 
Hg ≤ IOP ≤ 40 mm Hg, cup:disc ratio ≥0.6 and visual field mean deviation ≤−3. Ten patients who passed all 
inclusion criteria also had one affected first degree relative recruited to the study, even if they did not meet all 
inclusion criteria.
The entire MYOC gene was targeted for inclusion using a custom sequencing panel to include the intronic, 
exonic, UTR and promoter regions (Table 1) and an additional 1000 bp upstream of the Eukaryotic Promoter 
Database defined promoter coordinates (hg38 coordinates: chr1:171652678–171652737)29,30.
Library preparation and sequencing were performed in local laboratories, where DNA was simultaneously 
fragmented and tagged with sequencing adapters using the Illumina’s Nextera Rapid Capture Custom Enrichment 
kit (Illumina 5200 Illumina Way San Diego, California USA). Target regions of DNA were bound and ampli-
fied with custom capture probes and enriched prior to running on a Illumina NextSeq500 sequencing machine. 
Sequencing was performed in three batches of 96 samples and one batch of 84 samples.
Next generation sequencing (NGS) data were aligned against the human reference genome (hg38) using 
BWA-mem31. Variant calling was performed using GATK v3.732. Annotation was performed with ANNOVAR33 
against a database of RefSeq transcripts19, Exome Aggregation Consortium (ExAC)25, 1000 Genomes Project34,35 
and conservation-based pathogenicity scores of sort intolerant from tolerant (SIFT)36, PhyloP, PhastCons37 
and Genomic Evolutionary Rate Profiling (GERP++)38. Variants were also annotated with MutPred Splice39 
and Human Splicing Finder v3.0 (HSF3.0)40,41 to evaluate disruption of splicing. Further annotation was per-
formed using non-coding Functional Analysis through Hidden Markov Models (FATHMM)42,43 and Combined 
Annotation Dependent Depletion (CADD)44, and incorporation of the ‘Myocilin allele-specific glaucoma phe-
notype database’24.
For the 372 sequenced patient samples, coverage across both the MYOC gene and all targets were determined. 
The proportion of variants shared between samples was checked for consistency with known sample relationships 
and ethnicities. VerifyBamID v1.1.1345 software was used to estimate possible contamination and a ‘freemix’ 
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value threshold of >0.03 was applied46. Coverage statistics were generated using SAMtools v1.3.147 and BEDtools 
v2.17.048. A minimum threshold of 20X depth was used to distinguish samples with sufficient coverage.
For the entire region of the MYOC gene, depth per base was calculated with SAMtools v1.3.147 and conser-
vation scores were downloaded from the University of California Santa Cruz (UCSC) database for PhyloP37 and 
PhastCons37 databases of 20 mammals. Regions were considered in ‘high conservation’ if PhastCons ≥0.449 or 
PhyloP ≥1.550. Repetitive regions were annotated using UCSC RepeatMasker data, and rare variants (allele fre-
quency ≤ 0.05) in the POAG cohort and 1000 Genomes Project were plotted.
Variants were considered as previously known glaucoma-causing variants if they were identified as 
‘Glaucoma-causing’ in the ‘Myocilin allele-specific glaucoma phenotype database’ or ClinVar. Exonic variants 
were prioritised as candidate causal variants through CADD Phred scores ≥1551. Exonic splice variants were 
prioritised if they exceeded a 0.6 MutPred Splice score threshold39.
Non-coding variants were prioritised using FATHMM which out-performs CADD in the non-coding region 
whilst CADD has a superior classifier over FATHMM in the coding region. Variants were prioritised if the 
FATHMM score exceeded the default threshold of ≥0.543. Intronic variants were also prioritised if they were 
flagged as potentially splice affecting in HSF3.040,41.
CNVkit, which is designed for use with custom target panels and short-read Illumina sequencing, was used 
to infer copy number52. Data were analysed in batches to account for variation in average depth between batches, 
and a pooled reference of all samples within the batch was used.
Consent was obtained in accordance with the Declaration of Helsinki and was approved by South West 
Hampshire Local Research Ethics Committee (05/Q1702/8). Informed consent was obtained from all subjects, 
and all methods were carried out in accordance with the relevant guidelines and regulations of Research Ethics 
Committees (REC).
Results
samples analysed. 358 of 372 patients passed inclusion criteria after sample quality control. One sample 
was omitted due to insufficient depth (≤20X), five were omitted due to post hoc detection of sample duplication 
or mixed race individuals. A further eight samples were omitted due to the patient age at diagnosis being less 
than 40 years. Selected demographic and clinical characteristics for all 358 individuals in the final analysis are 
summarised in Table 2.
Genomic features and variation across the MYOC gene. The coordinates of the MYOC gene (5′ pro-
moter - 3′ UTR) are chr1:171,652,737–171,635,416 (hg38). Coverage was uninterrupted across the entire region 
with 100% coverage at 20X depth for all samples. The four batches had mean depths of 717X, 552X, 389X, and 
726X across target regions respectively, averaged across all samples. The poorest coverage was observed in batch 
3. A consistent coverage pattern is seen for all four batches (Fig. 1B) and was found to be correlated with mappa-
bility, repetitive context, conservation and GC content (R2 = 0.3358, p-value < 2.2 × 10−16). Conservation scores 
derived from PhastCons (Fig. 1C) and PhyloP (Fig. 1D) were highest across exonic regions, with smaller regions 
of high conservation in intron 1 and a region upstream of the Eukaryotic Promoter Database defined promoter 
region.
We identified a total of 172 annotated variants comprising 160 SNPs and 12 indels in the POAG cohort of 358 
individuals (Table 3). These variants were distributed across MYOC with 21 variants upstream intergenic, two 
variants in the promoter region, four in exon 1, 118 in intron 1, one in exon 2, 15 in intron 2, seven in exon 3, two 
in the 3′ UTR and two variants in the downstream intergenic region. 156 SNPs were identified in the non-coding 
regions of the MYOC gene in the POAG cohort. The majority (70.5%) of non-coding variants were located in the 
largest intron, intron 1, which spans 13,285 bp (76.7%) of the 17,321 bp length of MYOC. For comparison, there 
were 574 total SNPs in the 1000 Genomes Project European population (1000gEUR) in MYOC. There were 105 
rare (AF < 5%) variants in POAG and 134 rare (AF < 5%) variants in 1000gEUR, and these had a similar distri-
bution across the MYOC gene (Fig. 1F and G).
Three SNPs were identified with high conservation in PhastCons (20 mammals), using a threshold of 0.4, and 
excluding variants in repetitive regions. The variant rs76745622 was located in the upstream intergenic region 
whilst rs11586716 and rs12035960 were located in intron 1. No variants were identified in the non-coding regions 
with high conservation using PhyloP (≥1.5).
Chromosome Start End Length (bp)
Promoter 1 171652678 171652737 59
Prom-5′ UTR 1 171652633 171652678 45
5′ UTR 1 171652611 171652633 22
Exon 1 1 171652007 171652611 604
Intron 1 1 171638722 171652007 13285
Exon 2 1 171638596 171638722 126
Intron 2 1 171636709 171638596 1887
Exon 3 1 171635924 171636709 785
3′ UTR 1 171635416 171635924 508
Table 1. MYOC promoter, intronic, exonic and intergenic region locations within hg38 human reference genome.
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Figure 1. Per base analysis of variants and regions across the MYOC gene. Per base analysis of read depth, 
conservation scores, repetitive region context and allele frequency across the POAG patient data set (n = 358) 
for MYOC. (A) Gene structure of MYOC. (B) Per base depth for samples of batch 1, red; batch 2, green; batch 3, 
black; batch 4 orange;. (C) PhastCons 20 way mammals conservation score (20 mammals). (D) Phylop scores 
(20 mammals), showing measure of conservation (green) and acceleration (red). (E) Regions identified as 
repetitive regions by RepeatMasker (orange). (F) Allele frequency for each base’s detected alternate allele across 
358 POAG samples (left base position). (G) Allele frequency of SNPs in 1000 Genomes Project (European) for 
corresponding alternate alleles identified in F.
Min Max Mean Median SD
Age (years) 42 91 66 66 11
IOP (mmHg) 21.00 42.00 27.90 27.00 4.67
CDR 0.60 1.00 0.82 0.80 0.09
VFMD −31.54 −1.07 −14.52 −14.51 7.68
Table 2. Demographic and clinical characteristic summaries of age, intraocular pressure (IOP), cup:disc ratio 
(CDR) and visual field mean deviation (VFMD) for POAG cohort (n = 358).
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exonic variants. A total of 12 exonic variants were called (Table 4). Four SNPs were detected in exon 1, 
one SNP in exon 2 and seven SNPs in exon 3. Four variants had CADD Phred scores greater than 15 suggesting 
the variants were likely pathogenic. Variants NM_000261:exon3:c.C1102T (p.Q368*) and NM_000261:exon1:c.
C376T (p.R126W) had previously been identified as ‘Glaucoma-causing’ by the ‘myocilin allele-specific glaucoma 
phenotype database’. Variant p.R126W also had a high MutPred splice score of 0.605, indicating that this variant 
was likely to affect splicing.
Two variants NM_000261:exon2:c.G648A (p.K216K) and NM_000261:exon3:c.A1255G (p.T419A) not pre-
viously identified as glaucoma-causing, had pathogenicity scores indicating they may be of importance. In three 
individuals p.K216K had a high PhastCons score of 0.992 indicating that it is within a highly conserved element. 
The variant was also more common in the POAG cohort (AF = 0.0042) than in the ExAC Non-Finnish European 
(NFE) population (AF = 0.0005).
The missense variant p.T419A had no known rsID and was not found in ExAC NFE. In the POAG cohort it 
has an allele frequency of 0.0028, and identified as heterozygous in two individuals. It is located in exon 3 and has 
a SIFT score of 0, PolyPhen HDIV score of 0, GERP++ score of 4.52 and CADD Phred of 37 which indicate that 
this variant is likely to be highly pathogenic. However, this variant was found to be present on the same read pair 
as the p.Q368* variant in both patients (see Supplementary Fig. S1).
There was no significant difference in sub-phenotypes between patients with candidate causal MYOC variants 
(p.Q368*, p.R126W, p.K216K or p.T419A) and patients with no candidate causal MYOC variants (t-test, IOP 
p-value = 0.766, CDR p-value = 0.626, VFMD p-value = 0.211). However, hypertension was treated in five of the 
11 patients with candidate causal MYOC variants.
Three variants, p.E115K, p.G122G and p.R126W are clustered within the coiled-coil located at aa118-aa18620 
(Fig. 2). The aa117-aa166 region contains lysine residues responsible for dimerisation of MYOC53. The p.K216K 
variant is located in a linker region whilst p.T285T, p.D302D, p.Y347Y, p.Q368*, p.K398R, p.T419A and p.T438T 
are all located within the large olfactomendin-like domain.
Non-coding variants. There were 160 variants identified in non-coding regions (see Table 3 and 
Supplementary Fig. S2). The majority of variants (118) were identified within the largest region, intron 1.Using 
a FATHMM threshold of 0.5 to prioritise the non-coding variants, one variant upstream of the promoter, three 
intron 1 and one intron 2 variants remain (Table 5). The highest FATHMM score of 0.86 was seen for a common 
variant with an allele frequency of 10% in the 1000gEUR, and similar (8.2%) in the POAG cohort. A single var-
iant in intron 1, NM_000261.1:c.605-5949C>T, had a CADD Phred score greater than 15, however, there was 
no significant difference in frequency between this variant in the POAG cohort compared with the 1000gEUR 
cohort (allelic chi-squared test, p-value = 0.716). A second intron 1 variant, NM_000261.1:c.604+5942G>A, had 
a CADD Phred score of 12.78, a GERP++ score of 3.57 and PhastCons score of 0.504. Although pathogenicity 
scores are in favour of a potentially pathogenic effect, allele frequencies show no significant difference between 
the POAG cohort and 1000gEUR (allelic chi-squared test, p-value = 0.132). The novel intergenic upstream variant 
identified, NM_000261.1:c.-2851C>T, had a CADD Phred score of 11.19, a GERP++ score of 3.22 and low con-
servation PhastCons score of 0.0079 providing ambiguous indications of pathogenicity. This variant is not present 
in the 1000gEUR but is observed as heterozygous in one individual within the POAG cohort.
20 variants were flagged as ‘potentially splice altering’ by human splice finder (HSF) version 3.0, 18 of which 
had rsIDs (see Supplementary Table S2). 17 splice variants were in intron 1 (15 SNPs, and 2 insertions) and three 
in intron 2 (three SNPs). Of these, three variants had potential to introduce both a new splice acceptor and/or a 
splice donor site (AD), nine introduced a new slice acceptor site only (A), seven a new donor site only (D) and 
one breaks a branch point (BBP).
No copy number variants (CNVs) were detected within the MYOC gene region. There were no losses in copy 
number (CN) across the entire region, however, some (N = 113) samples were called as a single copy gain with a 
CN = 3 across the entire region.
Gene feature
No. variants
No. unique 
variants SNPs Indels
Intergenic us 21 21 0
Promoter 2 2 0
Promoter-5′ UTR 0 0 0
5′ UTR 0 0 0
Exon 1 4 4 0
Intron 1 118 110 8
Exon 2 1 1 0
Intron 2 15 12 3
Exon 3 7 7 0
3′ UTR 2 2 0
Intergenic ds 2 1 1
All 172 160 12
Table 3. Summary of the number of variants identified across all features of the MYOC gene.
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Discussion
We have performed targeted next-generation sequencing on the full region of the MYOC gene (promoter, UTRs, 
coding exons, introns and intergenic regions) on 358 POAG patients with severe POAG sub-phenotypes. We 
report all variants detected across the region and have performed an in silico analysis to assess pathogenicity. 
We identified a known pathogenic stop-gain in exon 3, a known pathogenic missense variant in exon 1, a known 
synonymous variant not previously considered pathogenic in exon 2, and an unknown missense variant in exon 
3. Between them these variants account for 11/358 (3.07%) of patients within our POAG cohort.
NM_000261:exon3:c.C1102T (p.Q368*) is the most common causal variant in POAG, accounting for 31.2% 
of disease-causing variants in MYOC24. This stop-gain is 6.5 times more common in our POAG cohort than in 
the 1000gEUR (allelic Fisher’s Exact test, p-value = 0.0336) and is seen in seven patients, accounting for 63.6% 
of the candidate causal variants identified. Of the seven patients with p.Q368* variants, three did not have a 
positive family history of POAG in our database. Craig et al. have previously shown a 100% family history for 
this variant, however this was only after retrospective follow up and new diagnoses were made. They found that 
the index patient was sometimes unaware of their family history of disease and thus family history reported may 
be underestimated, which may also be that case here. Furthermore, the penetrance of this variant is high but not 
complete. 82% of carriers of p.Q368* have POAG or OHT at the age of 65 years, and an unaffected carrier has 
been identified at 74 years of age54. Shepard et al. have previously shown that protein MYOC monomers with 
this variant do not contain a cryptic peroxisomal signalling sequence (PTS1) and that it likely exposes the PTS1 
sequence in its dimer partner16. This is believed to cause the mutant dimer to associate with the PTS1R and ulti-
mately cause deleterious trabecular meshwork cell function16. This mechanism has been supported by other stud-
ies55,56. Previous studies have shown that Caucasian patients with the p.Q368* variant have a mean IOP ranging 
between 27.3–35.4 mm Hg6,57–59, higher than in our study (mean IOP = 26.3 mm Hg). In our study, patients with 
No. Exon Chrom POS Ref Alt Variant type
Amino 
acid dbSNP144
1000 G 
EUR
ExAC 
NFE
Sample 
count
Study 
AF myocDB CLINSIG SIFT
gerp++ 
gt2
Phast 
Cons
CADD 
Phred
MutPred 
Splice
1 1 chr1 171,652,385 C T nonsynonymous R76K rs2234926 0.14120 0.13650 92 0.13700 Neutral Benign 0.049 3.43 0.945 9.00 0.116
2 1 chr1 171,652,269 C T nonsynonymous E115K rs757551979 — 0.00003 1 0.00140 — — 0.589 3.53 0.268 9.37 0.159
3 1 chr1 171,652,246 G A synonymous G122G rs145354114 — 0.00300 4 0.00559 Neutral Uncertain — — 0.000 0.17 0.494
4 1 chr1 171,652,236 G A nonsynonymous R126W rs200120115 — 0.00007 1 0.00140 Glaucoma — 0.019 −1.13 0.008 23.50 0.605
5 2 chr1 171,638,679 C T synonymous K216K rs141584495 — 0.00050 3 0.00419 Neutral — — — 0.992 15.63 0.165
6 3 chr1 171,636,585 C A synonymous T285T rs146606638 0.00800 0.00480 2 0.00279 Neutral Benign — — 0.591 14.00 0.126
7 3 chr1 171,636,534 G A synonymous D302D rs148433908 — 0.00030 1 0.00140 Neutral — — — 0.000 0.07 0.137
8 3 chr1 171,636,399 A G synonymous Y347Y rs61730974 0.02090 0.03050 17 0.02400 Neutral — — — 0.024 0.00 0.140
9 3 chr1 171,636,338 G A stopgain Q368* rs74315329 0.00200 0.00150 7 0.00978 Glaucoma Pathogenic — 4.52 0.283 37.00 0.374
10 3 chr1 171,636,247 T C nonsynonymous K398R rs56314834 0.00700 0.00480 10 0.01400 Neutral — 0.618 −1.17 0.843 3.87 0.268
11 3 chr1 171,636,185 T C nonsynonymous T419A — — — 2 0.00279 — — 0.000 5.04 0.945 23.50 0.196
12 3 chr1 171,636,126 G A synonymous T438T rs375235405 — 0.00004 1 0.00140 — — — — 0.898 11.66 0.125
Table 4. Annotation of all exonic variants in MYOC. Exon, exon number; Feature, genetic feature within 
MYOC; Chrom, chromosome; POS, location of 5′ base of variant in hg38; Ref, reference allele; Alt, alternate 
allele; Variant type, type of variant observed; Amino Acid, amino acid single letter abbreviation of reference 
amino acid and the amino acid substituted to; dbSNP144, rs ID if the variant is known; 1000 G EUR, allele 
frequency from 1000 Genomes Project (European ethnic sub-group); ExAC NFE, allele frequency from ExAC 
Non-Finnish European ethnic sub-group; Sample count, number of patients with the variant in the n = 358 
POAG cohort; Study AF, allele frequency of the variant within the n = 358 POAG cohort; myocDB, known 
MYOC variants database24; CLINSIG, pathogenicity of the variant in ClinVar; SIFT, sorts intolerant from 
tolerant substitutions; gerp++, Genomic Evolutionary Rate Profiling; PhastCons, conservation scoring and 
identification of conserved elements; CADD Phred, Combined Annotation Dependent Depletion on a Phred 
scale; MutPred Splice, machine learning-based predictor of exonic splice variants. Bold indicates variants which 
are causal candidates.
Figure 2. Human MYOC protein structure with its domains and variants mapped67,68. Additional annotation 
of coiled-coil domains are outlined in black (aa74-110 and aa118-18620). Green dots indicate a missense variant, 
purple dots indicate synonymous variants, whilst black dots indicate stop-gains.
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this variant had a mean CDR of 0.84, a mean VFMD of −13.84, and a mean age of 69.6 years. These findings agree 
with Graul et al. who found that p.Q368* patients did not have an earlier onset nor did they have a higher IOP57.
The known glaucoma-causing variant, NM_000261:exon1:c.C376T (p.R126W) was found in one of the 358 
POAG patients and had been previously reported as a late-onset familial variant60. It is a variant which is located 
on the protein dimer region of a coiled-coil. Gobeil et al. have shown cell adhesion properties were unaffected55 by 
this variant. NM_000261:exon1:c.C376T (p.R126W) had damaging SIFT and CADD Phred scores of 0.019 and 
23.5 respectively. There was very little evidence for splicing variation leading to POAG and only one previously 
known instance in MYOC of a predicted cryptic splice site reported within intron 161. However, a MutPred Splice 
score of 0.605 implicated that this variant contributes to the creation of a new donor splice site and a subsequent 
loss of 372 nucleotides from exon 1. This finding suggests that splice variants could be more important in POAG 
than previously known. Faucher et al. has previously shown that patients with this variant were found to have a 
mean IOP of 28.3 mm Hg and an age of onset of 7460. The patient with this variant in our cohort showed similar 
traits with a maximum IOP of 27 mm Hg and an age at diagnosis of 74 (see Supplementary Table S3).
The synonymous variant NM_000261:exon2:c.G648A (p.K216K) was not previously considered a patho-
genic variant. This variant is found in exon 2 which contains just one known pathogenic variant and is believed 
to translate to a linker region within the MYOC protein24,62. Synonymous variants in MYOC have been sug-
gested to have a role affecting MYOC mRNA structure and subsequently the translated protein stability63. Variant 
p.L215Q, on the preceding codon of p.K216, is believed to be glaucoma-causing on the basis of an in-silico 
damaging SIFT score62. Similarly, p.K216K has strong in silico pathogenicity scores to suggest possible patho-
genic status (PhastCons of 0.992 and CADD Phred of 15.63). Furthermore, this variant is found in the gnomAD 
Non-Finnish European (NFE) population25 significantly less frequently than the POAG cohort (allelic Fisher’s 
Exact test, p-value = 0.0109). This heterozygous variant was found in three patients from the University Hospital 
Southampton site. No evidence of relatedness was identified, however, there is a possibility that there is some 
distant relatedness which we do not have the capability to detect.
The missense variant NM_000261:exon3:c.A1255G (p.T419A) does not have an associated rsID, nor is it 
found within 1000gEUR or ExAC. However, it is found at an allele frequency of 8.952e-6 in the gnomAD NFE 
population. This variant has never been observed in a glaucoma context before but is seen as a heterozygote in two 
patients in this study (AF = 0.0028). This is a substantially higher frequency than gnomAD NFE (allelic Fisher’s 
Exact test, p-value = 9.4e-6). This variant had a SIFT score of 0, GERP++ score of 5.04, PhastCons of 0.945 and 
CADD Phred score of 23.5 which indicated further support for pathogenicity. However, we have found that in 
both patients p.T419A is co-inherited with the upstream p.Q368* variant (see Supplementary Fig. S1), therefore 
the protein will be truncated before translation of the potentially pathogenic substitution. Although these two 
patients had the earliest onset (50 & 56 years) of those carrying the p.Q368* variant, it is not possible to provide a 
plausible mechanism by which this variant could have a modifying effect.
Whilst there were no clear likely pathogenic variants in the non-coding region of the gene, NM_000261.1:c.-
2851C>T which is located in the upstream intergenic region (44694 bp from the neighbouring VAMP4 gene) 
was found to be of potential interest. Whilst it is not within a conserved element in PhastCons, it had damaging 
GERP++ and FATHMM scores. It has an allele frequency in the POAG cohort of 0.0014 (one heterozygous 
patient). This variant is not found within the 1000gEUR and is at a position not currently covered by gnomAD. 
The Ensembl regulatory build indicates that this variant could be functionally important as it is located at a poten-
tial CTCF binding site. All other variants with a FATHMM score ≥0.5 were seen at similar frequencies in both 
the POAG cohort and 1000gEUR. Genotyping this non-coding variant across a wider POAG cohort could prove 
informative. Variants located up to 1000 bp upstream of MYOC have been implicated as potentially functionally 
important for controlling IOP64,65.
No. Feature Chrom POS Ref Alt dbSNP144
1000 G 
EUR
Sample 
count
Study 
AF
gerp++ 
gt2 FATHMM
CADD 
Phred myocDB Repeat
Phast 
Cons
Regulatory 
build
1 INTERGENIC_US chr1 171655462 C T — — 1 0.00140 3.22 0.593 11.19 — 0 0.008
CTCF Binding 
Site
2 INTRON1 chr1 171,646,066 C T rs12035960 0.10440 55 0.08200 3.57 0.860 12.78 — 0 0.504
Promoter 
Flanking 
Region
3 INTRON1 chr1 171,644,671 G A rs75953590 0.01990 16 0.02200 — 0.551 15.38 — 0 0.244 —
4 INTRON1 chr1 171,643,942 G C rs144750384 0.00800 1 0.00150 — 0.623 10.31 — 1 0.061 Open chromatin
5 INTRON2 chr1 171,637,310 A G rs79263003 0.01090 10 0.01400 — 0.570 4.669 — 0 0.280 —
Table 5. Five non-coding variants in the MYOC region remain following initial filtering of the 160 non-coding 
variants with FATHMM ≥0.5. Feature, genetic feature within MYOC; Chrom, chromosome; POS, location 
of 5′ base of variant in hg38; Ref, reference allele; Alt, alternate allele; dbSNP144, rsID if the variant is known; 
1000 G EUR, allele frequency from 1000 Genomes Project (European ethnic sub-group); Sample count, number 
of patients with the variant in the n = 358 POAG cohort; Study AF, allele frequency of the variant within 
the n = 358 POAG cohort; gerp++, Genomic Evolutionary Rate Profiling; FATHMM, Functional Analysis 
through Hidden Markov Models; CADD Phred, Combined Annotation Dependent Depletion on a Phred scale; 
myocDB, known MYOC variants database24; Repeat, repetitive region as defined by RepeatMasker; PhastCons, 
conservation scoring and identification of conserved elements; Regulatory build, Ensembl Regulatory Build 
containing regions that are likely to be involved in gene regulation.
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Five rare variants were present in six individuals that potentially affect splicing. However, the presence of these 
variants in the European population cannot be confirmed due to lack of coverage in allele frequency databases 
for these sites.
We found no evidence of sub-gene copy number changes, and no whole gene deletions. We did predict 
some whole gene single copy gains and we suspect the predicted gain reflects within-batch depth variation. 
Patient selection criteria for this study used strict sub-phenotype parameters in order to select most severe 
POAG sub-phenotypes with a greater chance of an accurate POAG diagnosis. However, such criteria hinders 
genotype-phenotype analyses within the selected cohort. Genotyping of a larger POAG cohort not selected on 
sub-phenotypes is necessary in order to perform robust genotype-phenotype analyses. The MYOC gene accounts 
for ~3% of patients with POAG, therefore a larger cohort would also have greater power to detect rarer causal 
variants.
Conclusion
For the first time all regions of MYOC have been sequenced and analysed in a POAG cohort. We have identified 
two known pathogenic variants and two high pathogenic scoring variants, which may cause POAG in 11 patients. 
Synonymous and non-coding variants have been identified as having pathogenic qualities using in silico patho-
genicity predictions, and a known glaucoma-causing variant has been implicated as a potential deep exonic splice 
variant. This work expands the known allelic diversity of MYOC in POAG which is useful for diagnosis, genetic 
counselling and cascade genetic testing in families. Additional sequencing of MYOC interacting partners66 and 
other POAG-causing genes could reveal rare causal variants and provide further insight into the genetic basis of 
POAG.
Data Availability
Data generated or analysed during this study are included in this published article and its supplementary files.
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